Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.

Gralla, Richard J.; Navari, Rudolph M.; Hesketh, Paul J.; Popovic, W J; Strupp, John; Noy, Jose; Einhorn, Lawrence H.; Ettinger, David S.; Bushnell, William D.; Friedman, Carl J.

doi:10.1200/jco.1998.16.4.1568

Cited by 87 publications

(56 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We conducted this randomized, double-blind study to compare the efficacy and toxicity of two different 5HT 3 antagonists for the prevention of N/V during non-TBIcontaining conditioning therapy for HSCT. Standardized measures of nausea revealed no significant difference between granisetron and ondansetron and, although control of emesis decreased throughout the treatment period, the degree of success was similar between the two treatment groups.…”

Section: Discussionmentioning

confidence: 99%

“…Outside of the HSCT setting, numerous studies have concluded that these agents provide equivalent control of N/V induced by highly emetogenic chemotherapy when administered at equipotent doses. [2][3][4][5][6][7][8] Although three of these agents have been extensively studied in HSCT patients over the last 8 years, [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] limited data directly comparing these agents is available. [21][22][23] Ondansetron, the first 5-HT 3 receptor antagonist approved in the United States, has been the most widely studied and is most effectively used in combination with corticosteroids for prevention of CINV; granisetron's effects are also enhanced with the use of corticosteroids.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial

Walsh

Morris

Holle

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The serotonin type-3 (5-HT 3 ) antagonists represent a significant advance in the prevention of acute nausea and vomiting (N/V) from highly emetogenic chemotherapy. We sought to determine if any differences in efficacy or adverse effects exist between two such agents, ondansetron and granisetron, during conditioning therapy for hematopoietic stem cell transplantation (HSCT). Patients were randomized to receive either ondansetron 0.15 mg/kg intravenously every 8 h or granisetron 10 lg/kg intravenously daily. Additionally, all patients received scheduled dexamethasone and lorazepam. Prophylaxis was continued until 24 h after completion of chemotherapy. Nausea and distress were measured subjectively with visual analog scales and emetic episodes were quantified. Of the 110 randomized patients, 96 were evaluable for efficacy and safety. No significant differences in efficacy were observed between the ondansetron-and granisetron-treated patients, evaluated by comparing the degree of nausea and distress, number of emetic episodes and overall control of emesis. The adverse effects were also comparable and no patients were removed from study because of severe toxicities. This trial demonstrates that ondansetron and granisetron are equally effective at preventing acute N/V associated with conditioning therapy frequently used for HSCT. The agent of choice should be based on drug acquisition cost or preference.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial

Walsh

Morris

Holle

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…In directly comparative, single-agent studies of 5-HT 3 -receptor antagonists that permitted concomitant corticosteroid use [39,52], the addition of the steroid improved total control rates by 9.8%-13.4% at 24 hours and by 4.7%-8.7% at 48 hours postchemotherapy. Results from a study investigating optimum corticosteroid doses suggest that a dexamethasone dose of 20 mg be used as standard prophylaxis in combination with 5-HT 3 -receptor antagonists [72] ( Table 3).…”

Section: Potential For Corticosteroid Combinationmentioning

confidence: 99%

“…Data from animal studies have shown that the oral formulation reaches the gut directly, is absorbed across the proximal gut mucosa, and is immediately available to bind with 5-HT 3 receptors on the vagal afferent neurons [37,38]. Oral antiemetics can be more convenient for patients and may allow reductions in nursing time, in contrast with intravenous administration of the same agents [39].…”

Section: The Accepted Gold Standardmentioning

confidence: 99%

Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

Schnell¹

2003

The Oncologist

189

167

View full text Add to dashboard Cite

Nausea and vomiting are two of the most feared side effects of cancer chemotherapy and radiotherapy. Chemotherapy-induced nausea and vomiting can be broadly categorized as acute (occurring within 24 hours of therapy), delayed (persisting for 6-7 days after therapy), or anticipatory (occurring prior to chemotherapy administration). Breakthrough and refractory nausea and vomiting describe the symptoms of uncontrolled emesis. Evidence suggests that good control of nausea and vomiting during the acute period correlates with the control of delayed emesis. Conversely, protection failure during the first 24 hours has a high predictive value for delayed emesis in the same cycle.The 5-HT 3 -receptor antagonists, regarded as the 'gold standard' in antiemetic therapy, are the first-line treatment for moderately and highly emetogenic chemotherapy and radiotherapy regimens in adults and children. Evidence suggests that the 5-HT 3 -receptor antagonists administered in combination with corticosteroids afford the best protection from symptoms of acute emesis and, by extrapolation, the most effective prevention of delayed emesis.Antiemetic therapeutic guidelines stress that the goal of therapy is to prevent cytostatic-induced nausea and vomiting. Therefore, the prophylactic use of the most effective antiemetic regimen-taking into consideration the emetogenicity of the chemotherapy and individual patient characteristics-must be adhered to in order to prevent acute, delayed, and anticipatory nausea and vomiting.

show abstract

“…The use of 5-hydroxytryptamine-3 (5HT3) antagonists, such as dolasetron, granisetron and ondansetron, have contributed significantly to the control of nausea and vomiting in patients receiving moderately and highly emetogenic chemotherapy. [10][11][12][13] The great majority of patients receiving emetogenic chemotherapy at standard doses should achieve complete control of emesis at the present time.A number of patient and treatment-related factors predictive for the development of chemotherapy-induced emesis have been defined. These include age, gender, ethanol consumption history, and the intrinsic emetogenicity of the chemotherapy agents.…”

mentioning

confidence: 99%

Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support

Ballen

Hesketh

Heyes

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Considerable progress has been made in improving the control of chemotherapy-induced emesis. The impact of available antiemetic options for patients receiving stem cell transplants is unclear, as few prospective data have been collected. We prospectively evaluated antiemetic outcome in patients receiving stem cell transplantation over a 7-day period following the initiation of chemotherapy. The primary endpoints were the number of emetic episodes and the extent of nausea measured on a four-point scale. Eighty-two patients were evaluated. Ninety-five percent of patients had nausea during the first week of treatment; 80% had at least one emetic episode. The percentage of patients with emesis was as follows: day 1: 13%, day 2: 21%, day 3: 30%, day 4: 38%, day 5: 44%, day 6: 39%, day 7: 18%. In multivariate analysis, gender, emesis with prior chemotherapy, history of morning or motion sickness, type of transplant (auto vs allo), use of total body irradiation, or use of dexamethasone did not effect emesis control. Most patients receiving high-dose chemotherapy experience incompletely controlled emesis. Control of nausea and emesis progressively worsened with each subsequent day following initiation of chemotherapy, reaching a nadir on day 5. New treatment approaches are needed to improve emesis control in this patient population. Bone Marrow Transplantation (2001) 28, 1061-1066. Keywords: nausea; bone marrow transplantation Myeloablative chemotherapy and radiotherapy followed by autologous or allogeneic stem cell transplantation have been shown to be curative for certain hematologic malignancies, aplastic anemia, and genetic disorders. 1-3 Over the last three decades of transplantation, there have been significant advances in supportive management to lessen tox- icity and improve tolerance of autologous and allogeneic stem cell transplantation. [4][5][6][7] From the patient's standpoint, two of the most feared adverse effects of chemotherapy are treatment-induced nausea and vomiting. 8,9 Considerable progress has been made in the control of nausea and vomiting for patients receiving standard doses of chemotherapy. The use of 5-hydroxytryptamine-3 (5HT3) antagonists, such as dolasetron, granisetron and ondansetron, have contributed significantly to the control of nausea and vomiting in patients receiving moderately and highly emetogenic chemotherapy. [10][11][12][13] The great majority of patients receiving emetogenic chemotherapy at standard doses should achieve complete control of emesis at the present time.A number of patient and treatment-related factors predictive for the development of chemotherapy-induced emesis have been defined. These include age, gender, ethanol consumption history, and the intrinsic emetogenicity of the chemotherapy agents. 14 Also of importance is chemotherapy dose. The emetogenicity of a number of chemotherapy agents such as cisplatin and cyclophosphamide increases with increasing dose. 15 The outcome of antiemetic therapy has not been well studied in the setting of highdose chemo...

show abstract

Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.

Abstract: Oral granisetron, administered as a single 2-mg dose, provided equivalent total antiemetic control when compared with i.v. ondansetron (32 mg) in patients who received highly emetogenic, cisplatin-based chemotherapy.

Cited by 87 publications

References 15 publications

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial

Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support

Contact Info

Product

Resources

About